Edition:
India

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.67USD
9:01pm IST
Change (% chg)

$0.06 (+4.04%)
Prev Close
$1.61
Open
$1.68
Day's High
$1.72
Day's Low
$1.66
Volume
819,063
Avg. Vol
1,114,582
52-wk High
$2.14
52-wk Low
$0.73

Chart for

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $338.31
Shares Outstanding(Mil.): 294.18
Dividend: --
Yield (%): --

Financials

BRIEF-Novavax Inc Files For Mixed Shelf Of Up To $200 Mln

* NOVAVAX INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2zNiPwp) Further company coverage:

30 Dec 2017

BRIEF-Novavax Files Prospectus Supplement Related To Issuance, Sale Of Up To $75 Mln Of Common Stock

* NOVAVAX INC FILES PROSPECTUS SUPPLEMENT RELATES TO THE ISSUANCE AND SALE OF UP TO $75 MILLION OF COMMON STOCK -SEC FILING‍​ Source text: (http://bit.ly/2Edci1c) Further company coverage:

30 Dec 2017

BRIEF-Novavax Continues Phase 3 Trial Of RSV F Vaccine For Infants Via Maternal Immunization

* NOVAVAX CONTINUES PHASE 3 TRIAL OF THE RSV F VACCINE FOR INFANTS VIA MATERNAL IMMUNIZATION AND PROVIDES UPDATE ON PHASE 1/2 TRIAL OF THE NANOFLU™ VACCINE Source text for Eikon: Further company coverage:

19 Dec 2017

BRIEF-Novavax Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

08 Nov 2017

BRIEF-Novavax reports Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

08 Nov 2017

BRIEF-Novavax Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

09 Aug 2017

BRIEF-Novavax reports Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

09 Aug 2017

BRIEF-Novavax announces positive topline data from phase 2 trial and provides path forward for RSV F vaccine programs

* Novavax announces positive topline data from phase 2 older adult trial and provides path forward for RSV F vaccine programs Source text for Eikon: Further company coverage:

25 Jul 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF84.14 +0.60
Merck & Co., Inc. (MRK.N) $63.57 +4.91
Sanofi SA (SASY.PA) €73.34 +0.14
GlaxoSmithKline plc (GSK.L) 1,356.00 +3.00
AstraZeneca plc (AZN.L) 5,071.00 -59.00

Earnings vs. Estimates